119 related articles for article (PubMed ID: 20525754)
1. Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment.
Garrido-Laguna I; Janku F; Falchook GS; Fu S; Hong DS; Naing A; Aaron J; Wang X; Kies M; Kurzrock R
Clin Cancer Res; 2010 Aug; 16(15):4031-7. PubMed ID: 20525754
[TBL] [Abstract][Full Text] [Related]
2. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
Argiris A; Stenson KM; Brockstein BE; Mittal BB; Pelzer H; Kies MS; Jayaram P; Portugal L; Wenig BL; Rosen FR; Haraf DJ; Vokes EE
Head Neck; 2004 May; 26(5):447-55. PubMed ID: 15122662
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
Argiris A; Li Y; Forastiere A
Cancer; 2004 Nov; 101(10):2222-9. PubMed ID: 15452834
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
Gibson MK; Li Y; Murphy B; Hussain MH; DeConti RC; Ensley J; Forastiere AA;
J Clin Oncol; 2005 May; 23(15):3562-7. PubMed ID: 15908667
[TBL] [Abstract][Full Text] [Related]
5. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
[TBL] [Abstract][Full Text] [Related]
7. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
Argiris A; Li Y; Murphy BA; Langer CJ; Forastiere AA
J Clin Oncol; 2004 Jan; 22(2):262-8. PubMed ID: 14722034
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
[TBL] [Abstract][Full Text] [Related]
9. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.
Recondo G; Armand JP; Tellez-Bernal E; Domenge C; Belehradek M; De Vathaire F; Wibault P; Richard JM; Cvitkovic E
Laryngoscope; 1991 May; 101(5):494-501. PubMed ID: 1709437
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
[TBL] [Abstract][Full Text] [Related]
11. Absence of planned neck dissection for the N2-N3 neck after chemoradiation for locally advanced squamous cell carcinoma of the head and neck.
Lau H; Phan T; Mackinnon J; Matthews TW
Arch Otolaryngol Head Neck Surg; 2008 Mar; 134(3):257-61. PubMed ID: 18347249
[TBL] [Abstract][Full Text] [Related]
12. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390).
Forastiere AA; Shank D; Neuberg D; Taylor SG; DeConti RC; Adams G
Cancer; 1998 Jun; 82(11):2270-4. PubMed ID: 9610709
[TBL] [Abstract][Full Text] [Related]
13. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
[TBL] [Abstract][Full Text] [Related]
14. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
15. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.
Garrido-Laguna I; Janku F; Vaklavas C; Falchook GS; Fu S; Hong DS; Naing A; Tsimberidou AM; Wen S; Kurzrock R
Cancer; 2012 Mar; 118(5):1422-8. PubMed ID: 21823111
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
Elser C; Siu LL; Winquist E; Agulnik M; Pond GR; Chin SF; Francis P; Cheiken R; Elting J; McNabola A; Wilkie D; Petrenciuc O; Chen EX
J Clin Oncol; 2007 Aug; 25(24):3766-73. PubMed ID: 17704426
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience.
Wheler J; Tsimberidou AM; Moulder S; Cristofanilli M; Hong D; Naing A; Pathak R; Liu S; Feng L; Kurzrock R
Clin Breast Cancer; 2010 Feb; 10(1):46-51. PubMed ID: 20133258
[TBL] [Abstract][Full Text] [Related]
18. Outcome with neck dissection after chemoradiation for N3 head-and-neck squamous cell carcinoma.
Igidbashian L; Fortin B; Guertin L; Soulières D; Coulombe G; Belair M; Charpentier D; Tabet JC; Nguyen-Tan PF
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):414-20. PubMed ID: 19775825
[TBL] [Abstract][Full Text] [Related]
19. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience.
Papadimitrakopoulou VA; Dimery IW; Lee JJ; Perez C; Hong WK; Lippman SM
Cancer J Sci Am; 1997; 3(2):92-9. PubMed ID: 9099459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
